CDK 7 Inhibitors Market is Expected to Showcase a Significant Growth by 2034 | DelveInsight [Yahoo! Finance]
Syros Pharmaceuticals, Inc. (SYRS)
Last syros pharmaceuticals, inc. earnings: 3/5 06:57 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.syros.com
Company Research
Source: Yahoo! Finance
This growth is driven by a rise in cancer diagnoses, promising results from early-phase clinical trials of CDK inhibitors such as Samuraciclib and Q901, and the growing number of these inhibitors undergoing clinical trials and seeking approval from various companies. LAS VEGAS Sept. 25, 2024 /PRNewswire/ -- DelveInsight's CDK 7 Inhibitors Market Insights report includes a comprehensive understanding of current treatment practices, emerging CDK 7 inhibitors, market share of individual therapies, and current and forecasted CDK 7 inhibitors market size from 2020 to 2034, segmented into 7MM [ the United States , the EU4 ( Germany France Italy , and Spain ), the United Kingdom , and Japan ]. Key Takeaways from the CDK 7 Inhibitors Market Report As per DelveInsight's analysis, the total market size of CDK 7 inhibitors in the 7MM is expected to surge significantly by 2034. Leading CDK 7 inhibitor companies such as Carrick, Pfizer, Menarini Group, Roche, Qurient, Merck Sharp & Dohme,
Show less
Read more
Impact Snapshot
Event Time:
SYRS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SYRS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SYRS alerts
High impacting Syros Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
SYRS
News
- SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Syros Pharmaceuticals, Inc. - SYRSAccesswire
- Syros Pharmaceuticals Inc Is Being Investigated For Possible Securities Fraud And Investors Are Urged To Assist The Schall Law FirmAccesswire
- The Schall Law Firm Invites Shareholders To Join An Inquiry Into Syros Pharmaceuticals, Inc. For Violating Securities Laws Accesswire
- SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Syros Pharmaceuticals, Inc. - SYRSPR Newswire
- Syros Pharmaceuticals Inc Is Being Investigated For Possible Securities Fraud And Impacted Investors Are Urged To Contact The Schall Law FirmAccesswire
SYRS
Earnings
- 7/31/24 - Beat
SYRS
Analyst Actions
- 8/1/24 - HC Wainwright
SYRS
Sec Filings
- 9/18/24 - Form 4
- 9/18/24 - Form 4
- 9/12/24 - Form 4
- SYRS's page on the SEC website